

Special Issue

Drug Development and Repositioning Methodology on COVID-19

Message from the Guest Editors

Currently, a plethora of biomedical information is available concerning COVID-19. In this context, health professionals have been challenged with finding new insights into the mechanisms underlying actions, targets, and drugs. In particular, “drug-repurposing” is an efficient methodology that generates new therapeutics for approved drugs, but not new chemical compounds. Drug repurposing relies on data-driven approaches, such as bioinformatics, cheminformatics, and system biology, suggesting that integrated network pharmacology can elucidate the signaling pathways (mechanisms), targets, and compounds. These three components could result in a potential candidate to alleviate COVID-19. The submission of original articles, reviews, and hypotheses is welcome. Topics of interest for this issue include, but are not limited to:

- The protein–protein interaction networks in COVID-19;
- The relationship among signaling-pathways–targets–compounds in COVID-19;
- Network pharmacology-based investigation into COVID-19;
- COVID-19 and drug treatments, either dry-based or wet-based experiment.

Guest Editors

Dr. Ki Kwang Oh

Department of Bio-Health Convergence, College of Biomedical Science, Kangwon National University, Chuncheon 24341, Korea

Dr. Md Adnan

Department of Bio-Health Convergence, College of Biomedical Science, Kangwon National University, Chuncheon 24341, Republic of Korea

Deadline for manuscript submissions

closed (31 July 2023)



Current Issues in Molecular Biology

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed



mdpi.com/si/114772

Current Issues in Molecular Biology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cimb@mdpi.com

[mdpi.com/journal/
cimb](https://mdpi.com/journal/cimb)





Current Issues in Molecular Biology

an Open Access Journal
by MDPI

Impact Factor 3.0

CiteScore 3.7

Indexed in PubMed



[mdpi.com/journal/
cimb](http://mdpi.com/journal/cimb)

About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Madhav Bhatia

Department of Pathology and Biomedical Science, University of Otago,
Christchurch, 2 Riccarton Avenue, P.O. Box 4345, Christchurch 8140,
New Zealand

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PMC, PubMed, Embase, CAPlus / SciFinder, FSTA, AGRIS, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.3 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names are published annually in the journal.

